Kolon TissueGene is actively seeking to secure global partnerships ahead of the clinical data release for its osteoarthritis treatment, TG-C. The company aims to collaborate with global pharmaceutical firms in preparation for FDA approval and commercialization.
On June 25, Kolon TissueGene announced its participation in the BIO US 2026 conference in San Diego, California, and the IWOAI 2026 global osteoarthritis imaging conference in Munich, Germany.
With the first clinical data for TG-C set to be released in July, the company plans to focus on exploring collaboration opportunities with global pharmaceutical companies at these events. While last year’s discussions centered on development progress, this year will emphasize partnership discussions based on commercialization strengths, including patient cohort selection, insurance, and pricing strategies.
Kolon TissueGene intends to hold over 30 meetings with various companies, including global pharmaceutical firms, to discuss diverse partnership models such as technology exports and distribution and marketing collaborations.
At IWOAI 2026, the company will also share the latest trends in imaging techniques related to synovial inflammation, biomechanics, and the application of artificial intelligence in musculoskeletal imaging and clinical trial evaluation metrics.
Jeong Seung-ho, CEO of Kolon TissueGene, stated, "This year marks a critical point with the upcoming clinical data release and product approval application. We will expand our collaborations with global pharmaceutical companies while ensuring thorough preparations for approval."
Additionally, Kolon TissueGene recently obtained patents in the United States and Australia to expand the application of TG-C to degenerative spinal disease. The company plans to initiate clinical dosing procedures for spinal patients in the second half of this year and aims to pursue commercialization through joint development and licensing agreements.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.